2016-03-15T00:00:00.000-04:00
innovative market-based solutions,0.495099
North America,0.495295
U.S. commercialization strategy,0.391391
new product candidates,0.388507
Net loss,-0.464053
product candidates,0.388507
supply chain strategies,0.391391
business update,0.419843
global filing,-0.283678
global patient access,0.323602
contingent consideration,0.212892
pure-play biosimilar company,0.29191
high quality biosimilars,0.600833
biosimilar monoclonal antibodies,0.29191
financial results,0.522017
biologic innovation,0.600833
global registration study,0.288841
EPIRUS,0.24778
global development,0.29191
valuable in-market experience,0.53174
high drug costs,0.495099
quarter,-0.323137
